Advertisement

Topics

Netherlands Genomics Initiative NGI Company Profile

06:20 EST 18th December 2018 | BioPortfolio

NGI has released its Strategic Plan 2008 - 2012. Central elements of the plan are continuation of the national approach to genomics, increased emphasis on social and economic returns, and further strengthening of the knowledge base (research, technology and education).

Location

P.O. Box 93035
The Hague
2509 AA
Netherlands

Contact

Phone: 31 70 344 0672, +31 70 344 0640
Fax: 31 70 344 0632
Email: info@genomics.nl


News Articles [858 Associated News Articles listed on BioPortfolio]

AstraZeneca Joins Horizon\'s Genomics Discovery Initiative

Horizon Discovery's Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform

Educational Videos Use Poetry, Dance, Animation and Storytelling to Teach Elements of Genomics

The September issue of The Genomics Landscape highlights five new educational videos that were unveiled as a part of the '15 for 15' celebration to commemorate the 15th annivarsary of the completion ...

New Educational Videos Use Poetry, Dance, Animation and Storytelling to Teach Elements of Genomics

The September issue of The Genomics Landscape highlights five new educational videos that were unveiled as a part of the '15 for 15' celebration to commemorate the 15th annivarsary of the completion ...

M&As this week: 10x Genomics, Atlantic Research Group, AGC

10x Genomics has acquired Spatial Transcriptomics to enter the field of spatial genomics. The acquisition will enable 10x Genomics to gain...Read More... The post M&As this week: 10x Genomics, A...

Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, announces that AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s d...

10X Genomics Prepares to Hire 200 New Employees, Move into Larger Facility

Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.

CZI awards over $64 million to fight neurodegenerative disorders

(Chan Zuckerberg Initiative) Today, the Chan Zuckerberg Initiative (CZI) announced $64.25 million in funding and its selection of 17 early career investigators and nine collaborative science teams to ...

CZI awards over $51 million to fight neurodegenerative disorders

(Chan Zuckerberg Initiative) Today, the Chan Zuckerberg Initiative (CZI) announced $64.25 million in funding and its selection of 17 early career investigators and nine collaborative science teams to ...

Clinical Trials [545 Associated Clinical Trials listed on BioPortfolio]

Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response to IVF Drugs

The purpose of this study is to evaluate the effectiveness of a modified natural cycle in patients with previous poor response to infertility drugs, prior to proceeding to oocyte donation ...

Resuscitation Outcomes in the Netherlands

The Resuscitation Outcomes in the Netherlands - study assesses one-year survival and quality of life after In-Hospital Cardiac Arrest(IHCA). It's design is a multicenter prospective observ...

Southeast Netherlands Advanced Metastatic Breast Cancer Registry

The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of...

Ethical Dilemmas in Anaesthesiology in the Netherlands; a Qualitative Interview Study.

This study will describe which ethical dilemmas are experienced by anesthesiologist in the Dutch Healthcare system and what the current solving strategies are for these issues. Semi- struc...

Electronic Medical Records and Genomics (eMERGE) Phase III

The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clini...

Companies [886 Associated Companies listed on BioPortfolio]

Netherlands Genomics Initiative NGI

NGI has released its Strategic Plan 2008 - 2012. Central elements of the plan are continuation of the national approach to genomics, increased emphasis on social and economic returns, and further stre...

InteRNA Genomics

InteRNA Genomics B.V., a subsidiary of InteRNA Technologies B.V. and based in Bilthoven, the Netherlands, offers services and software for processing, analyzing and presenting ultra-high-throughpu...

Dyadic Nederland BV

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, the Netherlands that is dedicated to research and development activities for the benefit of Dyadic, ...

Genomics in Business

In 2003 Keygene initiated the first edition of Genomics in Business. It was the first conference to focus on the existing and future applications of genomics in the Agro-Food industry. With participan...

Genomics One Corporation

Genomics One is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and mono-clonal antibodies. The mission...

More Information about "Netherlands Genomics Initiative NGI" on BioPortfolio

We have published hundreds of Netherlands Genomics Initiative NGI news stories on BioPortfolio along with dozens of Netherlands Genomics Initiative NGI Clinical Trials and PubMed Articles about Netherlands Genomics Initiative NGI for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Netherlands Genomics Initiative NGI Companies in our database. You can also find out about relevant Netherlands Genomics Initiative NGI Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record